Loci Orthopaedics – an orthopaedic medical device company – announced the successful closing of an oversubscribed €12.8 million Series A financing. The funding round was led by new investors Seroba, Johnson & Johnson Innovation, JJDC, Inc., (JJDC) and the European Innovation Council (EIC) Fund.
Loci Orthopaedics creates novel technologies that target major unmet clinical needs in orthopaedic extremities. The company’s primary device (its patented InDx Implant System) is an innovative and evidence-based implant for thumb base joint arthritis. Thumb base joint arthritis is a highly and increasingly prevalent condition estimated to affect up to 5% of the US and EU population and 100 million people worldwide.
The InDx implant replicates the functional biomechanics of the thumb base joint to restore natural motion for those affected by this painful and disabling condition. InDx’s novel design could address the limitations of current thumb implants, which are often unsuccessful and prone to dislocation and movement post-implantation.
The Series A funding will enable the company to augment the initial clinical investigation, which indicates positive preliminary results, and develop additional clinical data to support regulatory approval applications and future commercialisation in different geographies.
In October 2023, Loci Orthopaedics completed enrolment of a 15-patient clinical study for its InDx Implant System. And the Thumb Hemi-Arthroplasty with Natural Kinematics study was designed to evaluate the surgical implantation of the device as well as improvements in pain, grip, and quality of life for those affected by thumb base joint arthritis. Results from the clinical study are expected to be published later this year.
KEY QUOTES:
“Thumb base joint arthritis is a painful and disabling condition with a significant unmet clinical need for an effective, evidence-based, surgical solution. With a growing patient population, our InDx Implant System has the potential to provide surgeons and patients with a less invasive and more effective treatment for this condition. This funding will enable us to expand our clinical programs, submit regulatory approval applications in the US and EU and accelerate our efforts towards future commercialisation.”
– Dr. Brendan Boland, Co-Founder and Executive Chairperson
“The company is excited to work with three very experienced and well-respected investment groups to help the company bring a promising new solution to market to help the many currently underserved patients and their surgeons with a joint sparing treatment option.”
– Barry Russell, CEO
“Orthopaedics extremities is one of the fastest growing areas in orthopaedics, so it is great to work with a company whose innovative solutions may positively disrupt the future treatment landscape for one of the most frequently performed surgeries in this space.”
– Maud Lazare, Head of Investor Relations at Seroba
“We are very happy to participate in this funding round. Loci Orthopaedics is disrupting the treatment landscape for one of the most frequently performed surgeries in orthopaedics extremities. The EIC’s unique financing approach, combining grants and equity, provides Europe’s most promising companies with means to develop and scale up their businesses in Europe.”
– Svetoslava Georgieva, Chair of the EIC Fund Board
